TICKERNERD
Menu
SEPNSEPNHealthcare · Biotechnology

SEPN Stock Forecast: Septerna, Inc. Price Predictions for 2026-2027

Last close, 15 Sept 2026
$39
−1.74% on the day

The 10 Wall Street analysts covering Septerna, Inc. hold a median 12-month price target of $51 — +31.2% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 91 of 100 as at 15 Sept 2026 — among the strongest tenth. Here, the model and the Street point the same way.

Market cap
$1.8B
Ticker Nerd rank
91 / 100
Median analyst target
$51
Analysts covering
10
Revenue$26.7M+22375.6% y/y
Operating income−$16.8M
Net income−$13.0M
Free cash flow−$22.2M
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+4.0%
1M
−12.7%
YTD
+39.4%
1Y
+168.6%
From 52W high
−19.4%
From 52W low
+170.0%
$14
$48
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

SEPN stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Septerna, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 15 Sept 2026
91 / 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Momentum
92
Growth
91
Accruals
90
Value
79
Revisions
68
Quality
60
Volatility
42
Issuance
42
Size
37

Momentum (92): The shares have been drifting up relative to others.

Issuance (42): The company has been issuing shares or taking on financing, diluting existing holders.

Size (37): Larger than most of the companies we track — more scrutinised, less often mispriced.

Built and run by Aslam Ghouse, an ex-Goldman Sachs quant trader with fourteen years in markets.

Wall Street

SEPN stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on SEPN, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$10$20$30$40$50$60Oct 25Jan 26Apr 26Jul 26SEPNHigh $62Median $51Low $48

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says10 analysts
10 Buy0 Hold0 Sell
Low $48Median $51High $62

The green dot is the last close — the median target sits +31.2% from it.

Recent analyst actionsNewest first

Of the 20 most recent actions, 6 moved their price target up and 1 moved it down.

DateFirmActionRatingTarget
19 Aug 2026JP MorganMaintainsOverweight$38 → $48
13 Aug 2026Jones TradingMaintainsBuy$43 → $62
12 Aug 2026HC Wainwright & Co.MaintainsBuy$40 → $60
12 Aug 2026Wells FargoMaintainsOverweight$48 → $50
11 Aug 2026GuggenheimMaintainsBuy—
11 Aug 2026GuggenheimMaintainsBuy$45 → $51
1 July 2026GuggenheimMaintainsBuy—
1 July 2026GuggenheimMaintainsBuy$52 → $45
1 July 2026HC Wainwright & Co.ReiteratesBuy—
1 July 2026HC Wainwright & Co.ReiteratesBuy$40
1 July 2026Truist SecuritiesMaintainsBuy$35 → $43
1 July 2026Truist SecuritiesMaintainsBuy—
8 June 2026Raymond JamesMaintainsStrong Buy—
13 May 2026HC Wainwright & Co.ReiteratesBuy—
14 Apr 2026HC Wainwright & Co.ReiteratesBuy—
24 Mar 2026JP MorganMaintainsOverweight—
11 Mar 2026Truist SecuritiesMaintainsBuy—
3 Mar 2026Wells FargoMaintainsOverweight—
2 Mar 2026HC Wainwright & Co.MaintainsBuy—
2 Mar 2026HC Wainwright& Co.MaintainsBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

Computed off the Friday close and sent before the US open.

Market Radar reports the week’s largest rank changes across roughly 4,600 US stocks, the factor behind each one, and where the market went. SEPN appears on the weeks it earns a place.

Free, every Monday. Unsubscribe any time.

Performance

SEPN vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 15 Sept 2026, Septerna, Inc. returned +168.6% against +15.9% for the S&P 500, dividends included.

SEPN vs S&P 500, last 12 monthsTotal return, rebased to 100
100150200250300Oct 25Jan 26Apr 26Jul 26SEPNS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

SEPN analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingNext fiscal year
Analysts raising
2
Analysts cutting
2
Fundamentals

Septerna, Inc. (SEPN) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−35.6×

Cheaper than 98% of US stocks

Price / sales
18.5×

Cheaper than 9% of US stocks

Price / book
4.6×

Cheaper than 22% of US stocks

EV / EBITDA
−26.6×

Cheaper than 91% of US stocks

Growth & margins
Revenue growth (YoY)
22375.6%

Higher than 99% of US stocks

Earnings growth (YoY)
22375.6%

Higher than 99% of US stocks

Gross margin
—
Operating margin
−62.9%

Higher than 16% of US stocks

Net margin
−24.5%

Higher than 14% of US stocks

Returns & dividend
Return on equity
−6.3%

Higher than 38% of US stocks

Return on assets
−7.1%

Higher than 29% of US stocks

Dividend yield
—

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Septerna, Inc. (SEPN) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Septerna, Inc. has a market value of $1.8B and an enterprise value of $1.4B.

  • Revenue in the twelve months to 30 June 2026: $98.9M. The latest quarter grew 22375.6% year on year.

  • Net income over the same four quarters: −$24.2M, a −24.5% net margin.

  • Diluted earnings per share, trailing twelve months: $−0.54.

  • Free cash flow in the twelve months to 30 June 2026: $105.1M.

  • Shares outstanding: 45.7M.

  • Trailing P/E: −35.6×; forward P/E: −20.2× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Septerna, Inc. employs 123 people — $804K of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 15 Sept 2026

Data provided by Twelve Data

Peers

SEPN vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
SEPNSepterna, Inc.$1.8B
91
KARDKardigan, Inc.$1.7B
0
STOKStoke Therapeutics, Inc.$1.8B
55
MRVIMaravai Lifesciences Holdings, Inc.$1.8B
85
VIRVir Biotechnology, Inc.$1.8B
93
XNCRXencor, Inc.$1.8B
78
BHVNBiohaven Ltd.$1.8B
32

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Septerna, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest SEPN news & analysis

Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewsWire · 10 Sept 2026neutral

Septerna announced it granted a non-qualified stock option for up to 275,000 shares to newly appointed Chief Medical Officer Rajiv Patni under the company's 2026 Inducement Plan, effective September 8, 2026. The award was made as an inducement material to Dr. Patni's employment consistent with Nasdaq Listing Rule 5635(c)(4).

Why it matters — This disclosure signals a key executive hire at Septerna and provides shareholders transparency into the equity compensation tied to the new Chief Medical Officer's appointment.

Septerna to Participate in Upcoming Investor Conferences

GlobeNewsWire · 1 Sept 2026neutral

Septerna, Inc., a clinical-stage biotechnology company focused on GPCR drug discovery, announced that its management will participate in several investor conferences scheduled for September. The company made the announcement on September 1, 2026, from its South San Francisco headquarters.

Why it matters — SUPER_WATCH watchers may be interested as these conference appearances offer an opportunity for investors to hear directly from management about the company's progress.

Septerna: GPCR Programs May Be Experimental, But I'm Holding For The Long Term

Seeking Alpha · 28 Aug 2026positive

Septerna has surged more than 315% since May 2025, driven by its GPCR-focused drug discovery platform and a collaboration with Novo Nordisk targeting GLP-1, GIP, and glucagon receptors. The company reported $26.7m in Q2 collaboration revenue, initiated a new R&D program, and has a pivotal Q1 2027 data readout for SEP-479, its oral small-molecule candidate for hypoparathyroidism.

Why it matters — SEPN watchers would care because the company's Novo Nordisk partnership and its SEP-479 pipeline candidate represent key revenue sources and a potential near-term catalyst for the stock.

Septerna Appoints Industry Veteran Rajiv Patni, M.D., as Chief Medical Officer

GlobeNewsWire · 25 Aug 2026positive

Septerna, Inc., a clinical-stage biotechnology company focused on GPCR drug discovery, announced the appointment of Rajiv Patni, M.D., as Chief Medical Officer. Dr. Patni brings more than 25 years of experience leading research, development, regulatory, and medical affairs organizations.

Why it matters — A new Chief Medical Officer with extensive biopharmaceutical leadership experience could strengthen Septerna's clinical development and regulatory capabilities as its programs advance.

Septerna, Inc. (SEPN) Reports Q2 Loss, Beats Revenue Estimates

Zacks Investment Research · 10 Aug 2026positive

Septerna, Inc. reported a Q2 loss of $0.29 per share, narrower than the Zacks Consensus Estimate of a $0.48 loss and improved from the $0.56 loss a year ago. The results surpassed revenue estimates as well.

Why it matters — SEPN watchers would note that the company's loss came in well below analysts' expectations, indicating better-than-anticipated quarterly performance.

FAQ

Frequently asked questions about SEPN stock

What is the SEPN stock price forecast for 2026-2027?

The 10 Wall Street analysts covering Septerna, Inc. have a median 12-month price target of $51, with estimates ranging from $48 to $62. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.

Is SEPN stock a buy right now?

Of the 10 analysts covering Septerna, Inc., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Septerna, Inc. 91 out of 100 across roughly 4,600 US stocks as at 15 Sept 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank SEPN?

As at 15 Sept 2026, Septerna, Inc. ranks 91 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (92 of 100).

Will SEPN stock go up?

No one can know that. What the data says: the median 12-month target from 10 analysts implies +31.2% from the last close, and Ticker Nerd's factor model ranks Septerna, Inc. 91 out of 100 as at 15 Sept 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.

What is the SEPN stock forecast for 2030?

No analyst covering Septerna, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for SEPN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $48 to $62 over the next 12 months.

How has SEPN stock performed over the past year?

Septerna, Inc. returned +168.6% over the 12 months to 15 Sept 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Septerna, Inc. do?

Septerna, Inc. is a clinical-stage biotechnology company focused on discovering and developing oral small-molecule therapies that target G protein-coupled receptors, or GPCRs.

What is the latest news on SEPN?

The most recent item we track (GlobeNewsWire, 10 Sept 2026): "Septerna, Inc. Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)". Septerna announced it granted a non-qualified stock option for up to 275,000 shares to newly appointed Chief Medical Officer Rajiv Patni under the company's 2026 Inducement Plan, effective September 8, 2026. The award was made as an inducement material to Dr. Patni's employment consistent with Nasdaq Listing Rule 5635(c)(4).

Company

About Septerna, Inc.

Septerna, Inc. is a clinical-stage biotechnology company focused on discovering and developing oral small-molecule therapies that target G protein-coupled receptors, or GPCRs. Its current programs address endocrine, immunology, inflammation, and metabolic disorders, with candidates under development for conditions such as hypoparathyroidism, chronic spontaneous urticaria, Graves’ disease, and thyroid eye disease. The company’s platform is designed to support the creation of medicines that can be taken by mouth, an approach that may improve treatment convenience across chronic disease areas. Septerna also advances research in metabolic and cardiometabolic biology through collaborations and internal drug discovery efforts. Headquartered in South San Francisco, California, Septerna operates within the biotechnology sector as a developer of experimental medicines aimed at hard-to-treat diseases.

CEO Dr. Jeffrey T. Finer M.D., Ph.D. · 123 employees · United States · https://septerna.com